文献速递艾滋病与性传播感染

接受注射用卡博特韦或替诺福韦酯/恩曲他滨进行HIV预防的妇女中HIV感染特征:HPTN 084研究

Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
PubMed 文献 · J Infect Dis · 2022-01-01

HPTN 084研究显示,在撒哈拉以南非洲妇女中,长效注射用卡博特韦(CAB)预防HIV感染优于每日口服替诺福韦酯/恩曲他滨(TDF/FTC)。本报告描述了揭盲前试验中发生的HIV感染:共40例,CAB组4例(1例基线感染,3例新发感染),TDF/FTC组36例新发感染。几乎所有新发感染发生时药物浓度不可定量或偏低,未检测到CAB耐药,TDF/FTC组中9例存在非核苷类逆转录酶抑制剂耐药,1例出现M184V突变。

要点

  • CAB组新发感染3例,其中2例无近期药物暴露且未注射CAB,1例注射延迟。
  • TDF/FTC组36例新发感染中,35例药物浓度提示低依从性或无依从性。
  • 所有感染病例均未检测到CAB耐药;TDF/FTC组9例有非核苷类逆转录酶抑制剂耐药,1例有M184V。

核心结论

  • 几乎所有新发HIV感染发生在药物浓度不可定量或偏低的情况下,未检测到CAB耐药。
  • 传播性非核苷类逆转录酶抑制剂耐药常见;1名妇女可能因研究药物暴露而获得核苷类逆转录酶抑制剂耐药。

研究设计与样本

  • HIV预防试验网络084(HPTN 084)揭盲前HIV感染的特征描述。
  • 检测方法包括HIV诊断试验、病毒载量检测、单拷贝RNA检测和HIV基因分型。
  • 采用液相色谱-串联质谱法测定血浆CAB、血浆TFV和红细胞内TFV-二磷酸浓度。

主要发现

  • 共识别40例HIV感染:CAB组4例(1例基线感染,3例新发感染);TDF/FTC组36例新发感染。
  • CAB组3例新发感染中,2例无近期药物暴露且未注射CAB,1例注射延迟。
  • TDF/FTC组36例中35例药物浓度提示低依从性或无依从性。
  • 所有病例均未检测到CAB耐药。
  • TDF/FTC组9例妇女存在非核苷类逆转录酶抑制剂耐药;1例存在核苷类逆转录酶抑制剂耐药突变M184V。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HIV Prevention Trials Network 084 demonstrated that long-acting injectable cabotegravir (CAB) was superior to daily oral tenofovir (TFV) disoproxil fumarate (TDF)/emtricitabine (FTC) for preventing human immunodeficiency virus (HIV) infection in sub-Saharan African women. This report describes HIV infections that occurred in the trial before unblinding. METHODS: Testing was performed using HIV diagnostic assays, viral load testing, a single-copy RNA assay, and HIV genotyping. Plasma CAB, plasma TFV, and intraerythrocytic TFV-diphosphate concentrations were determined by liquid chromatography-tandem mass spectrometry. RESULTS: Forty HIV infections were identified (CAB arm, 1 baseline infection, 3 incident infections; TDF/FTC arm, 36 incident infections). The incident infections in the CAB arm included 2 with no recent drug exposure and no CAB injections and 1 with delayed injections; in 35 of 36 cases in the TDF/FTC arm, drug concentrations indicated low or no adherence. None of the cases had CAB resistance. Nine women in the TDF/FTC arm had nonnucleoside reverse-transcriptase inhibitor resistance; 1 had the nucleoside reverse-transcriptase inhibitor resistance mutation, M184V. CONCLUSIONS: Almost all incident HIV infections occurred in the setting of unquantifiable or low drug concentrations. CAB resistance was not detected. Transmitted nonnucleoside reverse-transcriptase inhibitor resistance was common; 1 woman may have acquired nucleoside reverse-transcriptase inhibitor resistance from study drug exposure.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Eshleman SH, Fogel JM, Piwowar-Manning E, et al. Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084. J Infect Dis. 2022. PMID: 35301540. doi:10.1093/infdis/jiab576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。